Have you heard of FDA’s most recent guidance, Guidance for Industry 256: Compounding Animal Drugs from Bulk Drug Substances? If you haven’t heard of it, or you don’t know much about it - you’re not alone! In a recent survey, 90% of veterinary professionals reported that they were unaware of the guidance.
This edition of VerticalVet's Vet Med School, sponsored by Wedgewood Pharmacy, will cover everything you need to know before the April 1, 2023 enforcement date - including an overview of the guidance, how it will affect your veterinary practice, and how you can overcome the challenges presented by the guidance. Chief Veterinary Officer Dr. Ernie Ward is joined by the CEO of Wedgewood Pharmacy, Marcy Bliss, to prepare you and your practice for these significant changes to how you'll prescribe, access, and use compounded medications.
In this episode, we'll cover the following:
• Speaker introduction
• Overview of the agenda
• Brief definition of GFI 256
• Explanation of the established lists
• Overview of impact on veterinary practices
• How veterinarians can prepare for the April 1st enforcement date
• Available veterinary practice resources
• How to overcome the challenges GFI may present to your practice
For more information, visit www.wedgewood.vet/GFI
About our guest:
Marcy Bliss, CEO and Board Member, Wedgewood Pharmacy
Marcy A. Bliss is the CEO of Wedgewood Pharmacy, the leading compounding pharmacy for animals in the US. She leads the company's public affairs, strategic decision making and issues-management programs and is frequently seen on Capitol Hill, protecting patient and prescriber access to compounded medications.
Негізгі бет The Real Impacts of GFI 256 on Veterinary Practices sponsored by Wedgewood Pharmacy
No video
Пікірлер